VA|PREVENTION: Randomized Controlled Trial of a Person-Centred Digital Intervention to Prevent Diabetes in High-Risk Adults

Last updated: February 18, 2026
Sponsor: Egas Moniz - Cooperativa de Ensino Superior, CRL
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Diabetes (Pediatric)

Diabetes Prevention

Diabetes And Hypertension

Treatment

Type 2 Diabetes Guidebook

VA|PREVENTION web application (digital intervention)

Clinical Study ID

NCT07021144
VA|PREVENTION_01
  • Ages > 18
  • All Genders

Study Summary

The goal of this clinical trial is to help prevent the development of type 2 diabetes (T2D) in adults who are at risk. The study will test a digital intervention called VA|PREVENTION, a web application designed to support and promote healthy behaviour changes known has T2D risk factors, such as physical activity, diet, and sedentary behaviuor. The main questions this study will explore are:• Is the VA|PREVENTION web app, which includes a virtual human coach, effective in preventing type 2 diabetes?• Can the VA|PREVENTION web app be successfully implemented in real-world settings?• Is the VA|PREVENTION web app cost-effective?• Is it safe for participants to use?To answer these questions, the study team will compare the VA|PREVENTION web app to an openly available guidebook that provides standard information about preventing type 2 diabetes.Participants will complete the following activities:

  • Participants will be randomly assigned to one of two groups: one group will use the VA|PREVENTION app, while the other group will have access to an openly accessible guidebook on T2D prevention.

  • Participants will be in the study for 10 months.

  • Participants will be assessed at the start of the study (baseline), and again at 4 months and 10 months.

  • Assessments will include body measurements (such as weight, height, and waist circumference), physical activity levels, and responses to questionnaires.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years old;

  • FINDRISC Score ≥12 (moderate, high or very high) and/or prediabetes, defined aseither:

  • HbA1c between 5.7%-6.4% within the last two years; or

  • Impaired Glucose Tolerance (IGT) based on an Oral Glucose Tolerance Test (OGTT)at the 120-minute mark, with values between 140 and 199 mg/dL in the past threeyears;

  • Able to understand, speak and write Portuguese;

  • Able to provide written informed consent;

  • Access to a smartphone, tablet or computer with internet connection;

  • Plan to reside in the recruitment/study area for the next 10 months

Exclusion

Exclusion Criteria:

  • Established Type 1 and 2 Diabetes Mellitus diagnosis;

  • Pregnancy - Self-reported as currently pregnant, planning to become pregnant, or notpracticing contraception, in the following 10 months (if applicable);

  • Conditions precluding technology use (e.g. cognitive decline, dependent upon a carerfor daily activities);

  • Use of anti-obesity or diabetes medication, such as Metformin, Glucagon-likepeptide-1 analogue (GLP-1), or other medications known to significantly impactweight (either gain or loss), currently or within the preceding 3 months;

  • Following a prescribed medical diet;

  • Having undergone bariatric surgery within the past 3 years or planning surgerywithin the next 10 months;

  • Any mental health condition, including, but not limited to, eating disorders oralcohol/substance abuse, that would impact fully participating on the study;

  • Participating in a concurrent weight management program and/or relevantinterventional research protocol;

  • Contraindication to physical activity or weight loss;

  • Existing thyroid disorder;

  • Active cancer or less than 6 months from treatment;

  • Unable to provide informed consent or absence of a legal representative that canprovided it on behalf of the patient;

  • Institutionalised adults;

  • Foreseeable difficulty in attending study visits.

Study Design

Total Participants: 180
Treatment Group(s): 2
Primary Treatment: Type 2 Diabetes Guidebook
Phase:
Study Start date:
June 03, 2025
Estimated Completion Date:
November 25, 2026

Study Description

T2D risk adults will be invited by nurses and community pharmacists, leveraging their trusted roles within the healthcare system. Recruitment activities will prioritize fair treatment and respect for informed consent. Only participants fully capable of understanding the informed consent terms will be included in the study. Potential participants will receive detailed information about the study's purpose, procedures, potential risks, and benefits. After providing time for questions and discussion, written informed consent will be obtained. Following consent, participants will undergo screening to confirm eligibility according to predefined inclusion and exclusion criteria. Those meeting all eligibility criteria will proceed to the baseline visit (T0), during which initial assessments will be conducted. After the baseline assessment, participants will be randomized into one of the study groups. Following randomization, the assigned intervention will be initiated, with subsequent visits scheduled at 4 months (T1) and 10 months (T2) for data collection.Upon obtaining informed consent, participants will undergo screening to verify eligibility according to predefined inclusion and exclusion criteria. Those who meet all criteria will proceed to the baseline visit (T0), where initial assessments will be conducted. Following this, participants will be randomly assigned to one of the study groups. The assigned intervention will then be initiated, with subsequent visits scheduled at 4 months (T1) and 10 months (T2) for data collection. At these timepoints, waist circumference, the primary endpoint, as well as data on anthropometric measurements (heigh and weight), diabetes risk (FINDRISC score), dietary adherence (through MEDAS questionnaire), physical activity (through accelerometry measurements), and health resources utilization will be collected.

Connect with a study center

  • USF Cova da Piedade

    Almada 2271961, Almada 2809-010
    Portugal

    Site Not Available

  • USF Rosinha

    Seixal 2263115, Amora 2845-422
    Portugal

    Site Not Available

  • USF Charneca do Sol

    Almada 2271961, Charneca Da Caparica 2820-225
    Portugal

    Site Not Available

  • USF Inovar

    Almada 2271961, Corroios 2855-697
    Portugal

    Site Not Available

  • USF Saúde Laranjeiro

    Almada 2271961, Fernão Ferro 2810-186
    Portugal

    Site Not Available

  • USF Vista Tejo

    Almada 2271961, Monte Da Caparica 2825-023
    Portugal

    Site Not Available

  • Farmácia Alvide

    Alcabideche,
    Portugal

    Site Not Available

  • Farmácia Alvide

    Alcabideche 2272215,
    Portugal

    Site Not Available

  • Farmácia Largo do Coreto

    Almada,
    Portugal

    Site Not Available

  • Farmácia Nuno Álvares

    Almada,
    Portugal

    Active - Recruiting

  • Farmácia da Ramalha

    Almada,
    Portugal

    Active - Recruiting

  • USF São João do Pragal

    Almada,
    Portugal

    Active - Recruiting

  • Farmácia Largo do Coreto

    Almada 2271961,
    Portugal

    Site Not Available

  • Farmácia Nuno Álvares

    Almada 2271961,
    Portugal

    Site Not Available

  • Farmácia da Ramalha

    Almada 2271961,
    Portugal

    Site Not Available

  • USF São João do Pragal

    Almada 2271961,
    Portugal

    Site Not Available

  • Farmácia Romeiro

    Amadora,
    Portugal

    Site Not Available

  • Farmácia Romeiro

    Amadora 2271772,
    Portugal

    Site Not Available

  • Farmácia Santa Marta

    Barreiro,
    Portugal

    Site Not Available

  • Farmácia Santa Marta

    Barreiro 2271071,
    Portugal

    Site Not Available

  • Farmácia Vale Fetal

    Caparica,
    Portugal

    Site Not Available

  • Farmácia Vale Fetal

    Caparica 2270229,
    Portugal

    Site Not Available

  • USF Costa do Mar

    Costa da Caparica,
    Portugal

    Site Not Available

  • USF Costa do Mar

    Costa da Caparica 7116497,
    Portugal

    Site Not Available

  • Farmácia Quinta da Luz

    Lisboa,
    Portugal

    Site Not Available

  • Farmácia Quinta da Luz

    Lisbon 2267057,
    Portugal

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.